SPI 017

Drug Profile

SPI 017

Alternative Names: SPI-017; SPL-017

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Antidementias; Fatty acids; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain; Peripheral arterial disorders

Most Recent Events

  • 18 Mar 2013 Phase-II clinical trials in Pain associated with lumbar spinal stenosis in USA (IV)
  • 18 Mar 2013 Discontinued - Phase-I for Peripheral arterial disorders in Japan (IV)
  • 28 Feb 2010 Sucampo Pharmaceuticals initiates enrolment in a phase I trial (multiple-dose escalation) for Peripheral arterial disorders in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top